Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen

Less than a year after the FDA cleared Bristol-Myers Squibb $BMY and AbbVie’s $ABBV approved Empliciti injection for intravenous use in combination with Celgene’s $CELG pomalidomide (Pomalyst, or Imnovid, depending on which side of the Atlantic you are) and the steroid dexamethasone for relapsed, refractory multiple myeloma, the European Commission has followed suit.